[Oncolytic potential of recombinant influenza A virus vectors on a model of malignant glioma in vivo].

Malignant glioma is the most frequently occurring primary brain tumor. Despite significant progress in the diagnostics and treatment of neoplastic diseases the prognosis for patients with III-IV grade gliomas, remains extremely unfavorable. Rapidly developing area in oncology is the employment of therapeutic viruses with natural or genetically engineered oncolytic activity. In the present study we demonstrated the oncolytic potential of a recombinant influenza A virus vector with impaired interferon antagonism function of NS1 protein in treatment of malignant glioma. Recombinant influenza A virus (HA-DS-GFP) expressing green fluorescent protein from the NS1 open reading frame was used as a model vector. HA-DS-GFP virus has shown infectivity towards glioma cells both in vitro, and in vivo (experimental glioma model in rats). Intratumoral inoculation of HA-DS-GFP resulted in a substantial inhibition or complete regression of tumor growth. Our data demonstrate that recombinant influenza vectors have promising potential in therapy of malignant gliomas.

Hematological and toxicogenomic effects of ferromagnetic screening of natural electromagnetic fields.

Aftereffects of ferromagnetic screening on the hematological and toxicogenomic parameters in rats were traced over 45 days. Two-day ferromagnetic screening of male and female rats (reducing permanent constituent of magnetic field induction by 4-10 µT) led to leukopenia observed on day 14 of the experiment. Life-time evaluation of the toxicogenomic effects was carried out by rapid method for measurement of blood nucleotide DNA by fluorescent indication. In male blood leukocytes, increased aneuploidy and polyploidy were observed after 48 h of ferromagnetic screening and remained high on days 12 and 28 after screen removal. In contrast to males, leukocyte apoptosis in females was increased only 48 h after the start of ferromagnetic screening.